JP2008521920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521920A5 JP2008521920A5 JP2007544495A JP2007544495A JP2008521920A5 JP 2008521920 A5 JP2008521920 A5 JP 2008521920A5 JP 2007544495 A JP2007544495 A JP 2007544495A JP 2007544495 A JP2007544495 A JP 2007544495A JP 2008521920 A5 JP2008521920 A5 JP 2008521920A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- accession number
- genbank accession
- antibody
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 60
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 239000000611 antibody drug conjugate Substances 0.000 claims 11
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 11
- -1 polyethyleneoxy Polymers 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 6
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 102100032780 Semaphorin-5B Human genes 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 108010023729 Complement 3d Receptors Proteins 0.000 claims 4
- 102000011412 Complement 3d Receptors Human genes 0.000 claims 4
- 101000654679 Homo sapiens Semaphorin-5B Proteins 0.000 claims 4
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- 102100024220 CD180 antigen Human genes 0.000 claims 3
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims 3
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims 3
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000007942 carboxylates Chemical class 0.000 claims 3
- 239000000562 conjugate Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 3
- 101710129514 B-cell differentiation antigen CD72 Proteins 0.000 claims 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims 2
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000604039 Homo sapiens Sodium-dependent phosphate transport protein 2B Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 claims 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100037603 P2X purinoceptor 5 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 108091006232 SLC7A5 Proteins 0.000 claims 2
- 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 claims 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 2
- 150000003871 sulfonates Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 230000024704 B cell apoptotic process Effects 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 108010003455 BLyS receptor Proteins 0.000 claims 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010061298 CXCR5 Receptors Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 108010008955 Chemokine CXCL13 Proteins 0.000 claims 1
- 102000006574 Chemokine CXCL13 Human genes 0.000 claims 1
- 102100030886 Complement receptor type 1 Human genes 0.000 claims 1
- 230000004568 DNA-binding Effects 0.000 claims 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 1
- 101150051800 Fcrl1 gene Proteins 0.000 claims 1
- 108010014612 Follistatin Proteins 0.000 claims 1
- 102000016970 Follistatin Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101100119857 Homo sapiens FCRL2 gene Proteins 0.000 claims 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 claims 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 101000623899 Mus musculus Mucin-13 Proteins 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 102400000058 Neuregulin-1 Human genes 0.000 claims 1
- 108090000556 Neuregulin-1 Proteins 0.000 claims 1
- 101710189969 P2X purinoceptor 5 Proteins 0.000 claims 1
- 108010092528 Phosphate Transport Proteins Proteins 0.000 claims 1
- 102000016462 Phosphate Transport Proteins Human genes 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010080192 Purinergic Receptors Proteins 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108091006576 SLC34A2 Proteins 0.000 claims 1
- 102000009203 Sema domains Human genes 0.000 claims 1
- 108050000099 Sema domains Proteins 0.000 claims 1
- 108050003978 Semaphorin Proteins 0.000 claims 1
- 102000014105 Semaphorin Human genes 0.000 claims 1
- 101710199399 Semaphorin-5B Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000003618 TRPM4 Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 150000001356 alkyl thiols Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical group C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000011712 cell development Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000003831 deregulation Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 0 CC(C)C(C(N[C@@](CCCNC(N)=O)C(*(C)(C)*)=O)=O)N*(C(C)*)=C Chemical compound CC(C)C(C(N[C@@](CCCNC(N)=O)C(*(C)(C)*)=O)=O)N*(C(C)*)=C 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63261304P | 2004-12-01 | 2004-12-01 | |
| US60/632,613 | 2004-12-01 | ||
| PCT/US2005/043409 WO2006060533A2 (en) | 2004-12-01 | 2005-11-29 | Conjugates of 1, 8-bis-naphthalimides with an antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521920A JP2008521920A (ja) | 2008-06-26 |
| JP2008521920A5 true JP2008521920A5 (enExample) | 2008-12-25 |
| JP4993645B2 JP4993645B2 (ja) | 2012-08-08 |
Family
ID=36263731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544495A Expired - Fee Related JP4993645B2 (ja) | 2004-12-01 | 2005-11-29 | 抗体薬剤結合体および方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1817059A2 (enExample) |
| JP (1) | JP4993645B2 (enExample) |
| WO (1) | WO2006060533A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| US8070830B2 (en) | 2006-03-24 | 2011-12-06 | L'oreal S.A. | Fluorescent entity, dyeing composition containing at least one fluorescent entity comprising at least one heterocycle, with at least one internal cationic charge, and method for lightening keratin materials using said at least one fluorescent entity |
| FR2898902B1 (fr) * | 2006-03-24 | 2010-09-10 | Oreal | Colorants particuliers de type naphtalimide, composition tinctoriale comprenant au moins un tel colorant, procede de mise en oeuvre et utilisations |
| FR2898903B1 (fr) | 2006-03-24 | 2012-08-31 | Oreal | Composition de teinture comprenant un colorant disulfure fluorescent, procede d'eclaircissement des matieres keratiniques a partir de ce colorant |
| US7780743B2 (en) | 2006-03-24 | 2010-08-24 | L'oreal S.A. | Fluorescent entity, dyeing composition containing at least one fluorescent entity, and method for lightening keratin materials using said at least one fluorescent entity |
| WO2008033891A2 (en) * | 2006-09-12 | 2008-03-20 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Azonafide derived tumor and cancer targeting compounds |
| SI2474557T1 (sl) | 2007-07-16 | 2014-12-31 | Genentech, Inc. | Protiteles proti CD79b in imunokonjugati in postopki za uporabo |
| CL2008002083A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico |
| FR2921381B1 (fr) | 2007-09-21 | 2009-10-30 | Oreal | Colorant hemicyanine styryle thiol/disulfure, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant |
| FR2921373B1 (fr) | 2007-09-21 | 2009-10-30 | Oreal | Colorant derive d'indole styryle a linker alkylene, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant |
| FR2921376B1 (fr) | 2007-09-21 | 2009-10-30 | Oreal | Compose styryl tetrahydroquinolinium thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant |
| FR2921377B1 (fr) | 2007-09-21 | 2009-10-30 | Oreal | Compose styryl a motif hydroxy(cyclo)alkylamino thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant |
| US8119656B2 (en) | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
| WO2009089537A2 (en) * | 2008-01-11 | 2009-07-16 | Northwestern University | Anti-cancer compounds |
| RS54883B1 (sr) | 2008-01-31 | 2016-10-31 | Genentech Inc | Anti-cd79b antitela i imunokonjugati i metode upotrebe |
| WO2009144205A1 (en) | 2008-05-30 | 2009-12-03 | Basf Se | Rylene-based semiconductor materials and methods of preparation and use thereof |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2011221226A1 (en) | 2010-02-23 | 2012-08-16 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US8911732B2 (en) | 2010-12-20 | 2014-12-16 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| MX2014012889A (es) | 2012-05-01 | 2014-11-14 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17. |
| CN104411739B (zh) * | 2012-05-02 | 2017-03-08 | 路博润高级材料公司 | 芳族分散剂组合物 |
| JP6280103B2 (ja) | 2012-05-15 | 2018-02-14 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
| JP6192022B2 (ja) | 2012-05-21 | 2017-09-06 | ジェネンテック， インコーポレイテッド | 抗Ｌｙ６Ｅ抗体及びイムノコンジュゲート並びに使用方法 |
| US9463251B2 (en) | 2012-08-02 | 2016-10-11 | Genentech, Inc. | Anti-ETBR antibodies and immunoconjugates |
| EP2879708A4 (en) | 2012-08-02 | 2016-03-16 | Genentech Inc | ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES |
| CN103013497A (zh) * | 2012-12-21 | 2013-04-03 | 武汉大学 | 一种巯基荧光探针及其制备方法 |
| GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| KR20160055252A (ko) | 2013-09-17 | 2016-05-17 | 제넨테크, 인크. | 항-lgr5 항체의 사용 방법 |
| US9290578B2 (en) | 2013-10-21 | 2016-03-22 | Genentech, Inc. | Anti-Ly6E antibodies and methods of use |
| RS60349B8 (sr) | 2014-09-23 | 2022-10-31 | Hoffmann La Roche | Postupak upotrebe anti-cd79b imunokonjugata |
| CN107043406B (zh) | 2015-11-03 | 2021-08-17 | 财团法人工业技术研究院 | 化合物、连接子-药物、及配体-药物耦合体 |
| TR201618160A2 (tr) * | 2016-12-09 | 2018-06-21 | T C Istanbul Medipol Ueniversitesi | Parazi̇ti̇k ve neoplasti̇k hastaliklarin tedavi̇si̇nde kullanima uygun özgün i̇laç molekülleri̇ ve bunlarin hazirlanmasinda kullanilacak usuller |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CN107625771B (zh) * | 2017-09-27 | 2018-12-14 | 徐州玖胜医疗器械有限公司 | 一种miR-17基因抑制剂及用于治疗胃癌的用途 |
| TWI824043B (zh) | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
| TW202122116A (zh) | 2019-09-05 | 2021-06-16 | 西班牙商瑪製藥股份有限公司 | 藥物抗體偶聯物 |
| CA3175426A1 (en) | 2020-04-21 | 2021-10-28 | Alfonso Latorre Lozano | Drug antibody conjugates |
| CN116063284A (zh) * | 2023-02-10 | 2023-05-05 | 河南大学 | 一类含有与黏蛋白共价结合片段的肠限制性tgr5激动剂及其在治疗糖尿病药物中的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5416089A (en) | 1993-06-24 | 1995-05-16 | The Du Pont Merck Pharmaceutical Company | Polycyclic and heterocyclic chromophores for bis-imide tumoricidals |
| IL110460A (en) * | 1993-08-18 | 2001-01-11 | Basf Ag | Bis-naphthalimides, their preparation and pharmaceutical compositions containing them |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5561042A (en) * | 1994-07-22 | 1996-10-01 | Cancer Therapy And Research Center | Diamine platinum naphthalimide complexes as antitumor agents |
| US5641782A (en) * | 1995-02-16 | 1997-06-24 | The Dupont Merck Pharmaceutical Company | 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| JP3646191B2 (ja) | 1996-03-19 | 2005-05-11 | 大塚製薬株式会社 | ヒト遺伝子 |
| WO2001040309A2 (en) | 1999-10-29 | 2001-06-07 | Genentech, Inc. | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| ES2568625T3 (es) | 1999-11-29 | 2016-05-03 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| EP1311662A2 (en) | 2000-08-24 | 2003-05-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2420140A1 (en) | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2002215345A1 (en) | 2000-10-13 | 2002-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| WO2002054940A2 (en) | 2001-01-12 | 2002-07-18 | University Of Medicine & Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| DE60237917D1 (de) | 2001-06-05 | 2010-11-18 | Exelixis Inc | Gfats als modifikatoren des p53-wegs und verwendungsverfahren |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| AU2002347428A1 (en) | 2001-06-18 | 2003-01-02 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| AU2002318371B2 (en) | 2001-06-20 | 2006-06-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2002337657A1 (en) | 2001-07-25 | 2003-02-17 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2002362454A1 (en) | 2001-10-03 | 2003-04-14 | Origene Technologies, Inc. | Regulated breast cancer genes |
| AU2002365258A1 (en) * | 2001-10-12 | 2003-09-02 | University Of Vermont And State Agricultural College | Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
| US20050238650A1 (en) | 2002-04-17 | 2005-10-27 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2003055443A2 (en) | 2001-10-31 | 2003-07-10 | Alcon, Inc. | Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| WO2003089624A2 (en) | 2002-03-25 | 2003-10-30 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
| US20040022727A1 (en) | 2002-06-18 | 2004-02-05 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| US20040249130A1 (en) | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| KR20050048615A (ko) | 2002-08-19 | 2005-05-24 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| JP2004113151A (ja) | 2002-09-27 | 2004-04-15 | Sankyo Co Ltd | 癌遺伝子及びその用途 |
| US7276372B2 (en) | 2002-12-20 | 2007-10-02 | Pdl Biopharma, Inc. | Antibodies against GPR64 and uses thereof |
| US20050227301A1 (en) | 2003-01-10 | 2005-10-13 | Polgen | Cell cycle progression proteins |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| EP1594893A2 (en) | 2003-02-14 | 2005-11-16 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
-
2005
- 2005-11-29 JP JP2007544495A patent/JP4993645B2/ja not_active Expired - Fee Related
- 2005-11-29 WO PCT/US2005/043409 patent/WO2006060533A2/en not_active Ceased
- 2005-11-29 EP EP05852595A patent/EP1817059A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521920A5 (enExample) | ||
| JP2007514652A5 (enExample) | ||
| RU2412947C2 (ru) | Антитела, сконструированные на основе цистеинов, и их конъюгаты | |
| RU2006147264A (ru) | Коньюгаты антитело-лекарственное средство и способы | |
| JP2016514149A5 (enExample) | ||
| JP2008516896A5 (enExample) | ||
| JP2014534199A5 (enExample) | ||
| CN104220458B (zh) | 结合有含半胱氨酸残基的基序的修饰抗体，含该修饰抗体的修饰抗体-药物缀合物以及其制造方法 | |
| JP2013510093A5 (enExample) | ||
| JP2016510806A5 (enExample) | ||
| JP2011121969A5 (enExample) | ||
| RU2698727C9 (ru) | Ковалентные линкеры в конъюгатах антитело-лекарственное средство, способы их получения и применение | |
| JP2016530254A5 (enExample) | ||
| US12090210B2 (en) | Antibody-drug conjugate comprising modified antibody | |
| JP2024056715A5 (enExample) | ||
| JP2013544253A5 (enExample) | ||
| RU2011105402A (ru) | Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений | |
| HRP20151374T1 (hr) | Pirolobenzodiazepini i njihovi konjugati | |
| CN107652219B (zh) | 四马来酰亚胺型连接子及其应用 | |
| JP2019527673A5 (enExample) | ||
| CN103933575A (zh) | 一种三齿型连接子及其应用 | |
| CN106687141A (zh) | 吡咯并苯并二氮杂卓及其缀合物 | |
| JP2018533568A5 (enExample) | ||
| RU2006119643A (ru) | Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами | |
| KR101704379B1 (ko) | 항체-약물 접합체 및 그 제조방법 |